| Literature DB >> 35800265 |
Hong Chen1, Zi-Li Sun1, Miao-Xin Chen1, Yang Yang1, Xiao-Ming Teng1, Yun Wang2, Yuan-Yuan Wu1.
Abstract
Background: The predictors for live birth rate (LBR) following one episode of in vitro fertilization (IVF) cycle for patients using a "freeze-all" strategy are not entirely clear.Entities:
Keywords: In vitro fertilization (IVF); freeze-all strategy; frozen-thawed embryo transfer (FET); live birth rates (LBRs); prediction model
Year: 2022 PMID: 35800265 PMCID: PMC9253936 DOI: 10.21037/tp-21-589
Source DB: PubMed Journal: Transl Pediatr ISSN: 2224-4336
Figure 1Trial flow chart. An overview of all started FET cycles and the overall reproductive outcomes. FET, frozen-thawed embryo transfer; Pos.hCG, positive human chorionic gonadotropin; CP, clinical pregnancy.
Baseline characteristics of patients and their treatment cycles of IVF/ICSI
| Characteristics | Data |
|---|---|
| No. of IVF/ICSI cycles | 7,602 |
| No. of female | 7,602 |
| Patient characteristics | |
| Age at oocyte retrieval (year)★ | 32.28±4.85 |
| BMI (kg/m2)★ | 21.71±3.03 |
| Duration of infertility (years)▲ | 3 [2–5] |
| No previous pregnancy in couple, n (%) | 4,064 (53.46) |
| Previous pregnancy in couple, n (%) | 3,538 (46.54) |
| Previous delivery, n (%) | 730 (9.60) |
| Infertility etiology, n (%) | |
| Tubal | 3,782 (49.75) |
| Anovulatory | 273 (3.59) |
| Endometriosis | 180 (2.37) |
| Male factor | 898 (11.81) |
| Unexplained | 130 (1.71) |
| Other causes | 288 (3.79) |
| >1 type | 2,051 (26.98) |
| No. of previous IVF failures | 0 [0–1] |
| Year of oocytes retrieval, n (%) | |
| 2015 | 108 (1.42) |
| 2016 | 420 (5.52) |
| 2017 | 868 (11.42) |
| 2018 | 1,662 (21.86) |
| 2019 | 2,109 (27.74) |
| 2020 | 2,435 (32.03) |
| Treatment characteristics of ovarian stimulation cycle | |
| Total dose of gonadotrophin (IU)▲ | 1,800 (1,500–2,025) |
| Total duration of stimulation (days)▲ | 9 [8–10] |
| OSI▲ | 1.65 (1.20–2.08) |
| No. of oocytes collected▲ | 9 [5–15] |
| Method of fertilization, n (%) | |
| IVF | 5,249 (69.05) |
| ICSI | 2,353 (30.95) |
| No. of embryos created▲ | 6 [4–10] |
| No. of embryos frozen▲ | 4 [2–6] |
| Cleavage stage | 3 [2–5] |
| Blastocyst stage | 0 [0–1] |
★, values are presented as mean ± SD; ▲, values are presented as median (interquartile range). OSI = log (number of oocytes collected ×1,000/total dose of gonadotropin). OSI is a composite variable to measure ovarian response. IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; BMI, body mass index; OSI, ovarian sensitivity index; SD, standard deviation.
Cycle characteristics of FET
| Characteristics | Data |
|---|---|
| No. of FET cycles | 9,964 |
| No. of frozen treatments | |
| 1 | 7,602 (68.94) |
| 2 | 1,931 (19.38) |
| 3 | 370 (3.71) |
| 4 | 61 (0.61) |
| Type of FET cycles, n (%) | |
| Natural cycle | 2,766 (27.76) |
| Induced cycle | 3,905 (39.19) |
| Hormonal substitution cycle | 3,293 (33.05) |
| EMT (mm)★ | 10.80 (9.40–12.40) |
| Endometrial pattern, n (%) | |
| Heterogeneous pattern | 4,075 (40.90) |
| Homogeneous pattern | 5,094 (51.12) |
| Trilaminar pattern | 588 (5.90) |
| Missing | 207 (2.08) |
| E2 level on transplantation day (pg/mL)▲ | 174 (105–258) |
| P level on transplantation day (ng/mL)★ | 16.6 (11.3–22.5) |
| E2/P on transplantation day▲ | 10.86 (5.73–20.27) |
| Storage duration (days)★ | 124 (76–182) |
| Embryos thawed (n)▲ | 2 (2–2) |
| Damaged thawed embryos (n)▲ | 0 (0–0) |
| Embryos transferred (n)▲ | 2 (2–2) |
| Cleavage stage (n)▲ | 2 (2–2) |
| Blastocyst stage (n)▲ | 0 (0–1) |
| Top quality embryos transferred (n)▲ | 0 (0–1) |
★, values are presented as mean ± SD; ▲, values are presented as median (interquartile range). FET, frozen-thawed embryo transfer; EMT, endometrial thickness; E2, estradiol; P, progesterone; SD, standard deviation.
Clinical outcomes following FET cycles
| Characteristics | Data |
|---|---|
| FET 1, n (%) | |
| Positive β-hCG | 4,157/7,602 (54.68) |
| Preclinical losses to follow-up | 120/4,157 (2.89) |
| Biochemical pregnancies (preclinical losses) | 203/7,602 (2.67) |
| Ectopic pregnancy | 112/7,602 (1.47) |
| Clinical pregnancies | 3,722/7,602 (48.96) |
| Clinical losses to follow-up | 55/3,722 (1.48) |
| Abortion <12 weeks of gestation | 442/3,722 (11.88) |
| Abortion >12 weeks of gestation | 151/3,722 (4.06) |
| Live births | 3,066/7,602 (40.33) |
| Still births | 8/7,602 (0.11) |
| Deliveries | |
| Singleton | 2,211/3,074 (71.93) |
| Twin | 854/3,074 (27.78) |
| Triplet | 9/3,074 (0.29) |
| FET 2, n (%) | |
| Positive β-hCG | 985/1,931 (51.00) |
| Preclinical losses to follow-up | 21/985 (2.13) |
| Biochemical pregnancies (preclinical losses) | 61/1,931 (3.16) |
| Ectopic pregnancy | 32/1,931 (1.66) |
| Clinical pregnancies | 871/1,931 (45.11) |
| Clinical losses to follow-up | 13/871 (1.49) |
| Abortion <12 weeks of gestation | 101/871 (11.60) |
| Abortion >12 weeks of gestation | 31/871 (3.56) |
| Live births | 724/1,931 (37.49) |
| Still births | 2/1,931 (0.10) |
| Deliveries | |
| Singleton | 540/726 (74.38) |
| Twin | 186/726 (25.62) |
| Triplet | 0 |
| FET 3, n (%) | |
| Positive β-hCG | 178/370 (48.11) |
| Preclinical losses to follow-up | 5/178 (2.81) |
| Biochemical pregnancies (preclinical losses) | 13/370 (3.51) |
| Ectopic pregnancy | 8/370 (2.16) |
| Clinical pregnancies | 152/370 (41.08) |
| Clinical losses to follow-up | 2/152 (1.32) |
| Abortion <12 weeks of gestation | 23/152 (15.13) |
| Abortion >12 weeks of gestation | 3/152 (1.97) |
| Live births | 124/370 (33.51) |
| Still births | 0 |
| Deliveries | |
| Singleton | 94/124 (75.81) |
| Twin | 30/124 (24.19) |
| Triplet | 0 |
| FET 4, n (%) | |
| Positive β-hCG | 22/61 (36.07) |
| Preclinical losses to follow-up | 0 |
| Biochemical pregnancies (preclinical losses) | 1/61 (1.64) |
| Ectopic pregnancy | 0 |
| Clinical pregnancies | 21/61 (34.43) |
| Clinical losses to follow-up | 2/21 (9.52) |
| Abortion <12 weeks of gestation | 4/20 (20.00) |
| Abortion >12 weeks of gestation | 0 |
| Live births | 15/61 (24.59) |
| Still births | 0 |
| Deliveries | |
| Singleton | 12/15 (80.00) |
| Twin | 3/15 (20.00) |
| Triplet | 0 |
| Total FETs, n (%) | |
| Positive β-hCG | 5,342/9,964 (53.61) |
| Preclinical losses to follow-up | 146/5,342 (2.73) |
| Biochemical pregnancies (preclinical losses) | 278/9,964 (2.79) |
| Ectopic pregnancy | 152/9,964 (1.53) |
| Clinical pregnancies | 4,766/9,964 (47.83) |
| Clinical losses to follow-up | 72/4,766 (1.51) |
| Abortion <12 weeks of gestation | 570/4,766 (11.96) |
| Abortion >12 weeks of gestation | 185/4,766 (3.88) |
| Live births | 3,929/9,964 (39.43) |
| Still births | 10 |
| Deliveries | |
| Singleton | 2,857/3,939 (72.53) |
| Twin | 1,073/3,939 (27.24) |
| Triplet | 9/3,939 (0.23) |
All pregnancies are counted, showing the total reproductive outcome. Twins are counted as one live birth. FET, frozen-thawed embryo transfer; hCG, human chorionic gonadotropin.
LBR within each FET cycle and CLBRs across all FET cycles for 7,602 patients undergoing 9,964 FET cycles
| Cycle No. | No. of cycles | No. of live births | LBR within each cycle, % (95% CI) | CLBRs across all FET cycles, % (95% CI) | |
|---|---|---|---|---|---|
| Optimal estimatea | Conservative estimateb | ||||
| 1 | 7,602 | 3,066 | 40.33 (39.23, 41.44) | 40.33 (39.23, 41.44) | 40.33 (39.23, 41.44) |
| 2 | 1,931 | 724 | 37.49 (35.33, 39.70) | 62.70 (61.60, 63.79) | 49.86 (48.72, 50.99) |
| 3 | 370 | 124 | 33.51 (28.72, 38.58) | 75.20 (74.22, 76.17) | 51.49 (50.36, 52.62) |
| 4 | 61 | 15 | 24.59 (14.46, 37.29) | 81.30 (80.41, 82.17) | 51.68 (50.55, 52.81) |
a, it was based on the assumption that women who discontinued treatment would have had the same chance of a pregnancy resulting in a live birth as those who remained in treatment; b, it was based on the assumption that none of the women who discontinued treatment would have had a live birth. LBR, live-birth rate; FET, frozen-thawed embryo transfer; CLBRs, cumulative live birth rates; CI, confidence interval.
The effect and importance of predictors on live birth associated with freeze-all policy, with their categories, ORs with CIs, P values and adequacies
| Parameter | Value | OR (95% CI) | P value | Adequacy |
|---|---|---|---|---|
| FET cycle number | 1 (reference) | 1 | NA | |
| 2 | 0.891 (0.741, 1.071) | 0.218 | ||
| 3 | 0.609 (0.402, 0.923) | 0.019 | ||
| 4 | 0.235 (0.061, 0.913) | 0.036 | ||
| EMT | ≤8 mm (reference) | 1 | 0.938 | |
| >8 mm, ≤12 mm | 1.423 (1.006, 2.013) | 0.046 | ||
| >12 mm | 1.777 (1.261, 2.505) | <0.001 | ||
| Age at oocyte retrieval | <31 years (reference) | 1 | 0.082 | |
| 31–35 years | 0.779 (0.672, 0.903) | <0.001 | ||
| 36–40 years | 0.516 (0.411, 0.648) | <0.001 | ||
| >40 years | 0.125 (0.074, 0.210) | <0.001 | ||
| No. of oocytes collected | 0–5 (reference) | 1 | 0.027 | |
| 6–10 | 0.900 (0.734, 1.105) | 0.314 | ||
| 11–15 | 0.968 (0.768, 1.220) | 0.780 | ||
| 16–20 | 0.742 (0.564, 0.975) | 0.032 | ||
| >20 | 0.895 (0.651, 1.230) | 0.493 | ||
| No. of previous IVF failures | 0.921 (0.876, 0.967) | <0.001 | 0.025 | |
| No. of embryos frozen | Blastocyst stage | 1.078 (1.020, 1.140) | 0.008 | 0.022 |
| Cleavage stage | 1.062 (1.020, 1.104) | 0.003 | 0.017 | |
| Duration of infertility | 0.968 (0.944, 0.994) | 0.015 | 0.014 | |
| No. of blastocyst transferred | 1.446 (1.229, 1.701) | <0.001 | 0.006 |
ORs, odds ratios; CIs, confidence intervals; FET, frozen-thawed embryo transfer; EMT, endometrial thickness; IVF, in vitro fertilization.
Figure 2CLBRs stratified according to the categorical variables of positive significance in multivariate model. (A,B) Show the conservative and optimistic CLBRs stratified according to EMT, respectively. (C,D) Show the conservative and optimistic CLBRs stratified according to female age at oocyte retrieval, respectively. (E,F) Show the conservative and optimistic CLBRs stratified according to the number of oocytes collected, respectively. The conservative CLBRs were based on the assumption that none of the women who discontinued treatment would have had a live birth. These two curves show the best- and worst-case estimates of the CLBRs in the study group. The optimal CLBRs were based on the assumption that women who discontinued treatment would have had the same chance of a pregnancy resulting in a live birth as those who remained in treatment. These CLBRs reflect the worst- and best-case estimates, respectively. CLBRs, cumulative live birth rates; EMT, endometrial thickness.
Figure 3Kaplan-Meier curves for CLBRs among all women in the study. The optimal CLBRs were based on the assumption that women who discontinued treatment would have had the same chance of a pregnancy resulting in a live birth as those who remained in treatment. The conservative CLBRs were based on the assumption that none of the women who discontinued treatment would have had a live birth. These two curves show the best- and worst-case estimates of the CLBRs in the study group. CLBRs, cumulative live birth rates.